USA flag logo/image

An Official Website of the United States Government

Selection-driven plant metabolites for treatment of CNS diseases

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44AA018226
Solicitation Year:
2013
Solicitation Topic Code:
NIAAA
Solicitation Number:
PA11-335
Small Business Information
NAPROGENIX, INC
KTRDC - U.K. - AgTecc Laboratories Lexington, KY 40546-0236
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Selection-driven plant metabolites for treatment of CNS diseases
Agency: HHS
Contract: 2R44AA018226-03A1
Award Amount: $1,019,366.00
 

Abstract:

DESCRIPTION (provided by applicant): This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein. This is achieved bysubjecting mutant plant cells to selection pressures favoring the survival of mutants with the phenotype of interest. As an example, this approach will be used to optimize pharmacological activity in Lobelia cardinalis, which inhibits the human dopamine transporter (hDAT), putatively by its ability to synthesize the complex alkaloid, lobinaline. A stable transgenic line of L. cardinalis plant cells expressing the hDAT has been established. These cells show increased sensitivity to toxins transported into the cell by the hDAT, including the neurotoxin MPP+. A large, genetically diverse, population of gain-of-function mutants expressing the hDAT has now been generated, and selected on medium containing 100uM MPP+, which kills the vast majority of the transgenic mutants. However, individual mutants that are over-producing inhibitors of the hDAT have a survival advantage, so that the MPP+-resistant population is greatly enriched in clones with this bioactivity. Preliminary GC/MS analysis of individual MPP+-resistant mutants with increased hDAT inhibitory activity indicates that many of these are overproducing lobinaline, but the rest are generating other metabolites, some of which are not detectable in the wild-type plant. Phase II is designed to demonstrate that this biotechnology can be used to (a) generate novel natural products with a specific valuable pharmacology (b) provide a biosynthetic production system for these compounds in mutant plants. The process should be of particular value when a plant-derivedlead compound, such as lobinaline, is too complex for chemical synthesis. The first specific aim is to analyze the remaining MPP+-resistant population to determine those individuals in which lobinaline content cannot explain increased hDAT inhibitory activity. Separation (assay-guided preparative HPLC) and tentative identification (GC/MS) of active compounds will be followed by pharmacological evaluation in vitro, in comparison with lobinaline and a synthetic inhibitor of the hDAT. The most active compounds will then be tested for functional effects on the DAT in rat brain in vivo using electrochemistry. In parallel studies, the mutant clonal cultures which are overproducing active metabolites to the greatest extent will be regenerated to intact mutant plants, and extracts analyzed to establish whether the pharmacological /chemical phenotype is retained. The ultimate aim is to commercialize the technology as a platform for discovering and producing novel plant-derived natural products targeted on specific human CNS proteins. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Plants are a major source of existing medicines, but the pharmaceutical industry has now almost abandoned this source in favor of synthetic chemicals. One reason is that plant metabolites are often too complex for synthetic methods to be used for their modification or production. The technology being developed by Naprogenix uses the plants own biosynthetic capacity to modify the active chemicals contained in the plant. It is alsocapable of increasing the amounts of the active chemicals that are present. The directed evolution of a plant species using this technology is capable of generating novel compounds that may be of value in many CNS diseases, for example the targets in this project are important in drug dependence and neurodegenerative disease.

Principal Investigator:

John M. Littleton
859-257-1085
john.littleton@uky.edu

Business Contact:

Cindy A. Burklow
859-257-1127
cindy_burklow@yahoo.com
Small Business Information at Submission:

NAPROGENIX, INC
KTRDC - U.K. - AgTecc Laboratories Lexington, KY 40546-0236

EIN/Tax ID: 157114499
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No